MedTrace Logo

SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis

NCT07384234 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-02-03

No results posted yet for this study

Summary

This study is a prospective, randomized, two-cohort trial designed to evaluate the efficacy and safety of two regimens in the treatment of gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis: SHR-1701 combined with intravenous and intraperitoneal paclitaxel plus S-1, or SHR-1701 combined with CAPOX.

Conditions

  • Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

SHR-1701

SHR-1701, 1800mg, Q3w

DRUG

Capecitabine

Capecitabine, Q3W

DRUG

S-1

S-1, Q3W

DRUG

Paclitaxel

Paclitaxel,Q3W

DRUG

Oxaliplatin

Oxaliplatin, Q3W

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Yanan Zheng · Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2028-12-30
Completion
2030-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07384234 on ClinicalTrials.gov